Genetic testing has become an increasingly valuable part of cerebral palsy diagnosis — especially when imaging is normal, when CP features are atypical, or when family history raises questions. Knowing when testing makes sense and what it can tell you helps families decide whether to pursue it.
A decade ago, genetic testing was rarely part of CP diagnostics. Today, it’s increasingly standard — especially in major pediatric centers and especially when traditional workup leaves cause unclear. Studies have shown that genetic testing identifies a contributing cause in up to 25% of CP cases tested. For some families, that finding ends years of uncertainty. For others, it changes treatment. For still others, it shapes decisions about future pregnancies.
This guide covers how genetic testing fits into CP diagnostic workup — what it can find, when it’s recommended, what the experience involves, and how genetic counseling supports families through the process. For the broader picture of how genetics contributes to CP causation, see our deeper guide on genetic factors in cerebral palsy; this page focuses on the diagnostic side.
Genetic screening for CP looks for specific changes in a child’s DNA that may have caused or contributed to their CP. Unlike screening for known carrier conditions, CP genetic testing is exploratory — it casts a wide net across many genes that might be involved.
The shift from “CP is purely a birth-related condition” to “CP often has genetic contributors” has happened largely in the past 15 years, driven by the falling cost of DNA sequencing. What used to require years of lab work to investigate now takes weeks. The result is that genetic testing has moved from research curiosity to clinical option for many CP cases.
What the testing actually examines:
Most families starting genetic workup for CP get WES first, often combined with CMA. The combination catches both small mutations and larger structural changes.
What earlier genetic testing offers:
One thing parents sometimes find confusing: in most cases, identifying a genetic contributor doesn’t make CP “not CP.” The clinical CP diagnosis stays in place because the motor symptoms, the early onset, and the non-progressive course are all still there. The genetic finding is an additional layer of information about why the CP happened. The exception is when testing reveals a progressive genetic condition — some forms of hereditary spastic paraplegia, leukodystrophies, or metabolic disorders — which actually do change the diagnosis to that specific condition rather than CP.
The genes most commonly involved in CP affect specific aspects of brain development — how neurons migrate, how they connect, how they tolerate stress. Identifying which gene is involved often points to which biological pathway was disrupted.
Research has identified dozens of genes consistently linked to CP-like presentations, and the list keeps growing. The genes cluster into recognizable functional groups, which is part of why understanding which gene is involved often clarifies what to expect clinically.
The gene categories most commonly identified in CP genetic testing:
Identifying which category is involved often shapes what comes next in care planning.
The practical workflow of genetic testing:
Trio testing — child plus both parents — is increasingly standard because it dramatically improves interpretation accuracy.
Genetic testing complements rather than replaces traditional CP diagnostic workup. The clinical exam, milestone tracking, and brain MRI still come first — genetic testing fills in gaps and adds precision when those tools leave questions unanswered.
The decision about when to add genetic testing has gotten clearer as the field has matured. Some scenarios make testing high-yield; others make it less likely to change anything. Knowing the difference helps families and clinicians decide together.
Where genetic testing fits in the standard workflow:
The integration matters because genetic results without clinical context can be misleading. A “variant of uncertain significance” in a CP-related gene might be meaningful, or might not — the clinical picture decides.
A typical genetics workup for CP looks like:
The honest limitations of genetic testing for CP:
Beyond diagnosis, genetic findings increasingly shape how CP is managed. Some findings change medication choices. Others identify treatable conditions previously missed. Still others inform the family-planning conversations that follow a CP diagnosis.
The clinical utility of genetic testing for CP — meaning, does it actually change what doctors do? — has grown as more genes are identified and more targeted treatments become available. Even when findings don’t change medical management, they often shape family planning, connect families to specialty resources, and provide closure on questions about cause.
How genetic findings can change treatment:
Genetic counselors are specialized professionals who help families navigate testing decisions and results. What they offer:
Most major children’s hospitals have pediatric medical genetics or neurology programs with genetic counselors on staff. Insurance typically covers counseling visits when ordered as part of a clinical workup.
One important nuance: identifying a genetic contributor doesn’t automatically mean the CP wasn’t also affected by what happened during delivery. Many cases involve genetic vulnerability plus a perinatal event that wouldn’t have caused harm in a child without that susceptibility. If something felt wrong about your delivery, a medical malpractice review may still be warranted even after a genetic finding. Our birth injury lawyers are familiar with these mixed-cause cases. Request a free case review.
Our nurse advocates can help you think through whether genetic testing makes sense in your situation and connect you with pediatric genetics specialists in your area. Get a free, confidential evaluation — no commitment, just direction.
Genetic testing for CP analyzes a child’s DNA to identify mutations or variants that may have caused or contributed to their CP. The most common form is whole-exome sequencing (WES), which reads all the protein-coding regions of the genome. Whole-genome sequencing (WGS) and chromosomal microarray are also used. The result is a list of genetic findings the geneticist interprets in clinical context.
Genetic testing helps in several ways: it can identify a specific cause when MRI doesn’t show one (about 15–20% of children with CP have normal imaging), it distinguishes CP from genetic conditions that mimic it (some of which are treatable), it informs recurrence-risk conversations for future pregnancies, and it can sometimes change treatment when a metabolic or pharmacogenetic finding is identified.
Reasons to consider genetic testing include unexplained CP (no clear cause from history or imaging), atypical features (movements or symptoms that don’t fit standard CP), family history of neurological conditions, MRI showing structural malformations consistent with genetic causes, or planning future pregnancies. Some adults with CP also pursue testing to inform their own family planning.
Recommendations vary by clinical scenario. Major pediatric centers increasingly recommend it when imaging is normal, when CP features are atypical, when family history suggests a genetic component, or when the clinical picture suggests a specific genetic syndrome. The American Academy of Neurology has issued guidance supporting genetic evaluation for unexplained CP. Insurance coverage continues to improve as evidence accumulates.
Benefits include clearer understanding of cause, ability to identify treatable conditions that may have been mislabeled as CP, recurrence-risk information for family planning, possible enrollment in clinical trials for specific genetic conditions, peace of mind when testing rules out genetic causes, and connection to specialty care for identified syndromes. Genetic findings sometimes also support legal review when CP was attributed to delivery events that may not have been the actual cause.
Costs vary widely. Whole-exome sequencing typically runs $1,500 to $5,000 before insurance. Chromosomal microarray costs $500 to $1,500. Targeted single-gene tests are cheaper. Insurance coverage has improved dramatically — many major insurers now cover testing when criteria are met, and academic centers often have research or clinical programs that reduce out-of-pocket costs. Discussing coverage with the genetics clinic before testing is standard.
The main types are: whole-exome sequencing (WES), which reads protein-coding regions and identifies most disease-causing mutations; whole-genome sequencing (WGS), which reads everything including non-coding regions; chromosomal microarray (CMA), which detects deletions, duplications, and structural abnormalities; and targeted gene panels, which look at specific gene sets relevant to CP. WES is the most commonly used initial test for unexplained CP.
Kelsey is an experienced surgical nurse with more than 10 years in hospital-based care, including leadership within the operating room. She has worked extensively with pediatric patients, refining her ability to support children and families during critical moments. As both a mentor and patient advocate, Kelsey is dedicated to promoting safety, communication, and compassionate care while helping families understand medical procedures, treatment options, and the realities surrounding birth injuries and pediatric conditions.
Our nurses, patient advocates and legal experts are solely focused on bringing you the latest cerebral palsy information, options for financial assistance and access to community support.
Editorial process →